Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular disease
Biotech
Ventyx's CV drug rapidly reduces cardio risk biomarker
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week.
James Waldron
Oct 23, 2025 9:45am
Kardigan fashions $254M series B for late-stage pipeline
Oct 14, 2025 9:00am
Medtronic clips EU approval for Penditure LAA implant
Oct 2, 2025 12:00pm
Siemens Healthineers to co-sell Micromate robot to angio suites
Sep 29, 2025 3:15pm
Heartflow's updated coronary plaque AI nets FDA clearance
Sep 24, 2025 12:00pm
US VC launches another biotech with China-licensed asset
Sep 17, 2025 10:30am
